BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 21640157)

  • 1. Bcl-2 is a better therapeutic target than c-Myc, but attacking both could be a more effective treatment strategy for B-cell lymphoma with concurrent Bcl-2 and c-Myc overexpression.
    Sasaki N; Kuroda J; Nagoshi H; Yamamoto M; Kobayashi S; Tsutsumi Y; Kobayashi T; Shimura Y; Matsumoto Y; Taki T; Nishida K; Horiike S; Akao Y; Taniwaki M
    Exp Hematol; 2011 Aug; 39(8):817-28.e1. PubMed ID: 21640157
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Establishment and characterization of a novel MYC/BCL2 "double-hit" diffuse large B cell lymphoma cell line, RC.
    Pham LV; Lu G; Tamayo AT; Chen J; Challagundla P; Jorgensen JL; Medeiros LJ; Ford RJ
    J Hematol Oncol; 2015 Oct; 8():121. PubMed ID: 26515759
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Concurrent activation of c-myc and inactivation of bcl-2 by chromosomal translocation in a lymphoblastic lymphoma cell line.
    Kiem HP; Nourse J; Saltman DL; Blume KG; Cleary ML
    Oncogene; 1990 Dec; 5(12):1815-9. PubMed ID: 2284100
    [TBL] [Abstract][Full Text] [Related]  

  • 4. U-2973, a novel B-cell line established from a patient with a mature B-cell leukemia displaying concurrent t(14;18) and MYC translocation to a non-IG gene partner.
    Boström H; Leuchowius KJ; Hallböök H; Nordgren A; Thörn I; Thorselius M; Rosenquist R; Söderberg O; Sundström C
    Eur J Haematol; 2008 Sep; 81(3):218-25. PubMed ID: 18510704
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FAS death domain deletions and cellular FADD-like interleukin 1beta converting enzyme inhibitory protein (long) overexpression: alternative mechanisms for deregulating the extrinsic apoptotic pathway in diffuse large B-cell lymphoma subtypes.
    Takahashi H; Feuerhake F; Kutok JL; Monti S; Dal Cin P; Neuberg D; Aster JC; Shipp MA
    Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3265-71. PubMed ID: 16740746
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Concurrent activation of MYC and BCL2 in B cell non-Hodgkin lymphoma cell lines by translocation of both oncogenes to the same immunoglobulin heavy chain locus.
    Dyer MJ; Lillington DM; Bastard C; Tilly H; Lens D; Heward JM; Stranks G; Morilla R; Monrad S; Guglielmi P; Kluin-Nelemans JC; Hagemeijer A; Young BD; Catovsky D
    Leukemia; 1996 Jul; 10(7):1198-208. PubMed ID: 8684002
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Troglitazone inhibits cell growth and induces apoptosis of B-cell acute lymphoblastic leukemia cells with t(14;18).
    Takenokuchi M; Saigo K; Nakamachi Y; Kawano S; Hashimoto M; Fujioka T; Koizumi T; Tatsumi E; Kumagai S
    Acta Haematol; 2006; 116(1):30-40. PubMed ID: 16809887
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD10 antigen expression correlates with the t(14;18)(q32;q21) major breakpoint region in diffuse large B-cell lymphoma.
    Fang JM; Finn WG; Hussong JW; Goolsby CL; Cubbon AR; Variakojis D
    Mod Pathol; 1999 Mar; 12(3):295-300. PubMed ID: 10102615
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical studies of TW-37, a new nonpeptidic small-molecule inhibitor of Bcl-2, in diffuse large cell lymphoma xenograft model reveal drug action on both Bcl-2 and Mcl-1.
    Mohammad RM; Goustin AS; Aboukameel A; Chen B; Banerjee S; Wang G; Nikolovska-Coleska Z; Wang S; Al-Katib A
    Clin Cancer Res; 2007 Apr; 13(7):2226-35. PubMed ID: 17404107
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polymerase chain reaction detection of cells carrying t(14;18) in bone marrow of patients with follicular and diffuse large B-cell lymphoma: the importance of analysis at diagnosis and significance of long-term follow-up.
    Papajík T; Jedlicková K; Kriegová E; Jarosová M; Raida L; Faber E; Hubácek J; Vondráková J; Pikalová Z; Indrák K
    Neoplasma; 2001; 48(6):501-5. PubMed ID: 11949845
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MYC translocation and an increased copy number predict poor prognosis in adult diffuse large B-cell lymphoma (DLBCL), especially in germinal centre-like B cell (GCB) type.
    Yoon SO; Jeon YK; Paik JH; Kim WY; Kim YA; Kim JE; Kim CW
    Histopathology; 2008 Aug; 53(2):205-17. PubMed ID: 18752503
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activation of the p53 pathway by the MDM2 inhibitor nutlin-3a overcomes BCL2 overexpression in a preclinical model of diffuse large B-cell lymphoma associated with t(14;18)(q32;q21).
    Drakos E; Singh RR; Rassidakis GZ; Schlette E; Li J; Claret FX; Ford RJ; Vega F; Medeiros LJ
    Leukemia; 2011 May; 25(5):856-67. PubMed ID: 21394100
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival.
    Johnson NA; Savage KJ; Ludkovski O; Ben-Neriah S; Woods R; Steidl C; Dyer MJ; Siebert R; Kuruvilla J; Klasa R; Connors JM; Gascoyne RD; Horsman DE
    Blood; 2009 Sep; 114(11):2273-9. PubMed ID: 19597184
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The clinical presentation and prognosis of diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC rearrangement.
    Le Gouill S; Talmant P; Touzeau C; Moreau A; Garand R; Juge-Morineau N; Gaillard F; Gastinne T; Milpied N; Moreau P; Harousseau JL; Avet-Loiseau H
    Haematologica; 2007 Oct; 92(10):1335-42. PubMed ID: 18024371
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [BCL-2 in primary central nervous system lymphomas. Immunohistochemistry and molecular biology].
    Buccoliero AM; Castiglione F; Caldarella A; Rossi Degl'Innocenti D; Taddei A; Ammannati F; Mennonna P; Taddei GL
    Pathologica; 2004 Oct; 96(5):425-9. PubMed ID: 15688978
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Frequency of Double Expresser in Selected Cases of High Grade Diffuse Large B-Cell Lymphomas.
    Naseem M; Asif M; Khadim MT; Ud-Din H; Jamal S; Shoaib I
    Asian Pac J Cancer Prev; 2020 Apr; 21(4):1103-1107. PubMed ID: 32334477
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ABT-263 sensitizes TRAIL-resistant hepatocarcinoma cells by downregulating the Bcl-2 family of anti-apoptotic protein.
    Wang G; Zhan Y; Wang H; Li W
    Cancer Chemother Pharmacol; 2012 Mar; 69(3):799-805. PubMed ID: 22037880
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Establishment of a human herpes virus-8-negative malignant effusion lymphoma cell line (STR-428) carrying concurrent translocations of BCL2 and c-MYC genes.
    Taira T; Nagasaki A; Tomoyose T; Miyagi J; Kakazu N; Makino S; Shinjyo T; Taira N; Masuda M; Takasu N
    Leuk Res; 2007 Sep; 31(9):1285-92. PubMed ID: 17368758
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanism of synergy of N-(4-hydroxyphenyl)retinamide and ABT-737 in acute lymphoblastic leukemia cell lines: Mcl-1 inactivation.
    Kang MH; Wan Z; Kang YH; Sposto R; Reynolds CP
    J Natl Cancer Inst; 2008 Apr; 100(8):580-95. PubMed ID: 18398104
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Bcl-2 inhibitor ABT-263 enhances the response of multiple chemotherapeutic regimens in hematologic tumors in vivo.
    Ackler S; Mitten MJ; Foster K; Oleksijew A; Refici M; Tahir SK; Xiao Y; Tse C; Frost DJ; Fesik SW; Rosenberg SH; Elmore SW; Shoemaker AR
    Cancer Chemother Pharmacol; 2010 Oct; 66(5):869-80. PubMed ID: 20099064
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.